Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer.
SEER Program
prostatic neoplasms/epidemiology
prostatic neoplasms/mortality
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Oct 2020
03 Oct 2020
Historique:
received:
22
09
2020
revised:
30
09
2020
accepted:
01
10
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Results (SEER) Research Data (2000-2017) were analyzed using the SEER*Stat software. The Kaplan-Meier method and Cox regression were used. Patients with de novo mPCa were allocated to three cohorts based on the year of diagnosis: A (2000-2003), B (2004-2010), and C (2011-2014). The maximum follow-up was fixed to 5 years. Overall, 26,434 patients were included. Age, race, and metastatic stage (M1) significantly affected OS and CSS. After adjustment for age and race, patients in Cohort C showed a 9% reduced risk of death (hazard ratio (HR): 0.91 (95% confidence interval [CI] 0.87-0.95),
Identifiants
pubmed: 33022939
pii: cancers12102855
doi: 10.3390/cancers12102855
pmc: PMC7650780
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Cancer. 2018 Jul 15;124(14):2931-2938
pubmed: 29723398
Cancers (Basel). 2019 Sep 12;11(9):
pubmed: 31547436
Clin Genitourin Cancer. 2017 Aug 31;:
pubmed: 28899723
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
Anticancer Res. 2019 May;39(5):2467-2473
pubmed: 31092441
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Oncol. 2020 Sep 7;2020:4986365
pubmed: 32963528
Prostate. 2018 Sep;78(12):889-895
pubmed: 29707790
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):420-427
pubmed: 30643173
J Clin Oncol. 2016 Mar 20;34(9):980-6
pubmed: 26811521
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
BJU Int. 2017 Dec;120(6):751-754
pubmed: 28834013
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553